Overview
The Touch® CMC Prosthesis is a dual-mobility implant for the surgical treatment of trapeziometacarpal (CMC) osteoarthritis, the form of arthritis at the base of the thumb most commonly known as rhizarthrosis. The dual-mobility configuration, borrowed from total hip arthroplasty, distributes motion across two articular surfaces and is the principal reason its published dislocation rate sits below 1%. By design the Touch® prosthesis delivers a 116° mobility cone, greater than the native CMC joint, with motion distributed symmetrically when the cup is positioned in the reference orientation.
KeriMedical, the Swiss manufacturer, has built the Touch® system around 144 implant configurations. The combinatorial breakdown is: 6 stem sizes (anatomical trilobe titanium stems with a titanium and hydroxyapatite dual coating), two cup shapes (spherical or conical, in two diameters of 9 mm and 10 mm, stainless steel with the same titanium and hydroxyapatite dual coating), and six neck options (three heights of 6 mm, 8 mm and 10 mm in either straight or 15° offset configurations). The mobile bearing is a highly cross-linked polyethylene (HXLPE) liner with a 4 mm head diameter. The implant is purpose-designed for the trapeziometacarpal joint, not a repurposed hip mini-prosthesis. Touch® is the first CMC1 prosthesis on the market to offer both spherical and conical cup options, and the first dual-mobility CMC1 prosthesis to use a highly cross-linked polyethylene liner.
Touch® is CE-marked Class III under EU MDR 2017/745 (notified body 2862), continuously since 2015; current MDR certification is valid through 15 February 2028. The implant is GESY-covered in Cyprus when implanted by a participating hand surgeon at a GESY-contracted hospital. (Touch® also holds FDA Premarket Approval P240020, granted 10 July 2025 - relevant as an additional regulatory credential, not a primary positioning point for the Cypriot market.) KeriMedical has been part of the Medartis Group since July 2025 and operates as a distinct hand-and-wrist brand within the group.
OrganoGEN is the exclusive Cyprus distributor and provides surgical support at every implantation.
Indications & Contraindications
Indicated For
- Trapeziometacarpal (CMC) osteoarthritis (rhizarthrosis)
- Painful CMC instability after failed conservative therapy of at least six months
- Post-traumatic CMC arthritis with preserved trapezium height
- Revision of failed trapeziectomy with adequate bone stock
Contraindicated For
- Active local or systemic infection
- Insufficient trapezial bone stock
- Skeletal immaturity
- Patient unable to comply with the post-operative protocol
Technical Specifications
| Manufacturer | KeriMedical SA, Geneva, Switzerland (Medartis Group since July 2025) |
|---|---|
| Configurations | 144 total (6 stems × 4 cup options × 6 neck options) |
| Stem | Titanium, anatomical trilobe section, dual coating (Titanium + hydroxyapatite). 6 sizes (XS, 0, 1, 2, 3, 4) |
| Cups | Stainless steel with dual coating (Titanium + hydroxyapatite). Two shapes (spherical, conical), two diameters (Ø9 mm and Ø10 mm). 4 total cup references |
| Liner | Highly cross-linked polyethylene (HXLPE) |
| Neck and head | Stainless steel. 3 heights (6 mm, 8 mm, 10 mm) in straight or 15° offset configurations. Head diameter 4 mm |
| Articulation | Dual-mobility, 116° mobility cone |
| Regulatory (EU) | CE-marked Class III, EU MDR 2017/745, notified body 2862. Continuously CE-marked since 2015. MDR certification valid through 15 February 2028 |
| Regulatory (US) | FDA PMA P240020, 10 July 2025 |
| Distribution in Cyprus | OrganoGEN Limited (exclusive) |
| GESY reimbursement | Approved (active ZC code) |
Clinical evidence
Comparative series. 0.5% dislocation with Touch® dual-mobility versus 4.2% with the legacy Arpe single-mobility implant (P=0.02).
Prospective study of 107 cases with minimum 3-year follow-up. Pain VAS dropped from 7.4 to 0.8 (p<0.001), Kapandji opposition score from 8.0 to 9.4, QuickDASH from 38 to 20 (p<0.01), key-pinch strength from 3.5 kg to 5.5 kg. 95% of patients very satisfied or satisfied. Zero dislocations at minimum 3-year follow-up.
Retrospective series of 92 prostheses. No major complications (dislocation, fracture or loosening). Functional QuickDASH scores not significantly different from age-matched general population. Mean return to work 2.6 months.
Prospective cohort, 130 patients. 96% implant survival at 2 years.
More than 30 Touch®-specific peer-reviewed publications and conference abstracts, including five-to-eight-year prospective follow-up data and a 150-prosthesis series at four years. Full bibliography available to qualifying surgeons on request.
GESY Coverage & Pricing in Cyprus
The Touch® CMC Prosthesis is GESY-covered under an active ZC code. When implanted by a participating hand surgeon at a GESY-contracted hospital, the device cost is included in the hospital reimbursement, and patients are not billed separately for the implant.
For self-pay or international patients, OrganoGEN provides hospital quotations on request. We do not publish list prices. Request a quote with your hospital's procurement details.
Frequently asked questions
Is the Touch® CMC Prosthesis covered by GESY in Cyprus?
Who manufactures the Touch® CMC Prosthesis?
What is the dislocation rate of the Touch® CMC Prosthesis?
Is the Touch® implant CE-marked?
Why are 144 configurations needed?
What is the polyethylene liner made of and why does it matter?
What functional improvement do patients see after Touch® CMC arthroplasty?
Where can patients have Touch® CMC arthroplasty in Cyprus?
More in Hand & Wrist
Other products OrganoGEN distributes in the Hand & Wrist category.
